Abstract
Lysine acetylation (Ac-K) is a critical post-translational modification that has been shown to play a fundamental role in epigenetic histone regulation1. Recent acetylome studies indicate that acetyl-lysine regulation expands well beyond histones, and can target thousands of proteins and many different cellular processes. Many of these acetylome studies often link changes in global acetylation to disease progression. Of interest, changes in the acetylated mitochondrial protein profiles are linked to neurologic, oncogenic, cardiac, and diabetic pathologies2. A recent study by Horton et al. specifically identified hyperacetylation of mitochondrial proteins in patients with heart failure3. As hyperacetylation of mitochondrial proteins appear to be a critical marker of metabolic disease, having tools to quickly access the acetylated mitochondrial state may be beneficial for diagnosis or treatment. A new, pan-acetyl-lysine antibody (Cat. # AAC02) was developed that can identify acetylated mitochondrial proteins by immunofluorescence. Importantly, this antibody was tested in combination with mitotracker, and co-localized with the mitochondrial marker; conversely, the acetyl-lysine antibody did not co-localize with the LAMP 1 lysosomal marker. This acetyl-lysine antibody identified acetylated mitochondrial proteins in fibroblast, epithelial, cardiomyocytes, and fibroblast-like cell lines highlighting its range of utility. Hydrogen peroxide, an important regulator of glucose metabolism, as well as class I/II and class III HDAC inhibitors were used to examine the antibodies ability to detect changes in mitochondrial acetylation profile. Level of acetylated mitochondrial protein changes in response to these various treatments were detected with the acetyl-lysine antibody. Surprisingly, class I/II HDAC inhibitor, TSA, promoted significant cell specific down regulation of mitochondrial acetylation, which was reversed with class III HDAC inhibitor treatment. This result supports previous publications showing crosstalk between class I/II and class III HDACs4,5; however, this is the first report implicating acetylation of mitochondrial proteins as a target of this crosstalk. In summary, these data highlight the ability of this novel antibody to detect and track mitochondrial acetylation, and may be a critical to gain a better mechanistic understanding of the role of HDACs in disease, and ultimately, may be an important diagnostic tool for dysfunctional mitochondrial related diseases.